Compare Stocks → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTXNASDAQ:CORVNASDAQ:ETONNASDAQ:MBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10+3.1%$0.08$0.01▼$0.72N/A1.271.32 million shs231,100 shsCORVCorrevio Pharma$0.42$0.41$0.21▼$2.79$27.80M0.085.35 million shsN/AETONEton Pharmaceuticals$3.28+0.9%$3.96$2.42▼$5.81$84.26M1.1767,857 shs23,227 shsMBIOMustang Bio$0.36+5.8%$1.00$0.33▼$8.17$3.74M1.59178,314 shs122,956 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%-21.57%CORVCorrevio Pharma0.00%0.00%0.00%0.00%0.00%ETONEton Pharmaceuticals+1.88%+0.93%-17.93%-27.29%-8.96%MBIOMustang Bio-0.47%-9.33%-68.52%-75.54%-91.98%Pentagon contract could send this $2 AI stock soaring (Ad)Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/ACORVCorrevio PharmaN/AN/AN/AN/AN/AN/AN/AN/AETONEton Pharmaceuticals2.1033 of 5 stars3.55.00.00.00.00.80.0MBIOMustang Bio1.9774 of 5 stars3.55.00.00.02.40.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTXAptinyxN/AN/AN/AN/ACORVCorrevio PharmaN/AN/AN/AN/AETONEton Pharmaceuticals3.00Buy$10.00204.88% UpsideMBIOMustang Bio3.00Buy$17.254,695.66% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/ACORVCorrevio Pharma$32.63M0.85N/AN/A($0.02) per share-21.00ETONEton Pharmaceuticals$31.64M2.66N/AN/A$0.60 per share5.47MBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/ACORVCorrevio Pharma-$35.18M-$0.79N/A∞N/A-107.81%-2,128.82%-58.56%N/AETONEton Pharmaceuticals-$940K-$0.03N/A∞N/A-2.96%-6.21%-3.17%5/9/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)Latest APTX, ETON, CORV, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023ETONEton Pharmaceuticals-$0.04-$0.09-$0.05-$0.09$7.70 million$7.31 million 3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTXAptinyxN/AN/AN/AN/AN/ACORVCorrevio PharmaN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTXAptinyxN/AN/AN/ACORVCorrevio Pharma22.541.070.95ETONEton PharmaceuticalsN/A1.651.60MBIOMustang BioN/A0.740.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTXAptinyxN/ACORVCorrevio Pharma7.30%ETONEton Pharmaceuticals27.86%MBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipAPTXAptinyx10.97%CORVCorrevio PharmaN/AETONEton Pharmaceuticals13.16%MBIOMustang Bio2.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTXAptinyx12N/AN/ANot OptionableCORVCorrevio Pharma13366.19 millionN/AOptionableETONEton Pharmaceuticals3025.69 million22.31 millionOptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableAPTX, ETON, CORV, and MBIO HeadlinesSourceHeadlineWorcester biotech down to 11 employees after asset sale stallsbizjournals.com - April 22 at 7:47 PMWorcester biopharmaceutical firm Mustang Bio to lay off 81% of staffwbjournal.com - April 18 at 1:45 PMBiotech cites federal review of deal with Chinese firm in latest staff cutsbizjournals.com - April 16 at 9:03 AMMustang Bio stock tumbles 27% amid news of mass layoffsmsn.com - April 15 at 5:59 PMMustang Bio announces major workforce reductioninvesting.com - April 14 at 11:56 AMMustang Bio to Cut Global Headcount by 81%marketwatch.com - April 12 at 8:56 PMMustang Bio Exploring MB-106 CAR T-Cell Candidate in Autoimmune Diseasesprecisionmedicineonline.com - March 29 at 3:32 PMMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseasesglobenewswire.com - March 28 at 9:00 AMMustang Bio, City of Hope CAR-T therapy extends survival in phase 1 glioblastoma trialfiercebiotech.com - March 12 at 1:35 PMMustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlightsglobenewswire.com - March 11 at 4:05 PMCAR T-Cell Therapy Shows Activity in Subgroup of Brain Tumor Patientstechnologynetworks.com - March 8 at 8:10 AMMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Gliomatmcnet.com - March 7 at 9:09 AMWhy Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarketmarkets.businessinsider.com - March 7 at 9:09 AMMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Gliomaglobenewswire.com - March 7 at 7:30 AMMustang Bio Inc (MBIO)uk.investing.com - February 13 at 2:36 PMMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conferencefinance.yahoo.com - January 11 at 9:29 AMMustang Bio Inc MBIOmorningstar.com - January 6 at 12:54 AMMustang Bio Stock (NASDAQ:MBIO) Dividends: History, Yield and Datesbenzinga.com - December 27 at 10:10 PMMBIO Mustang Bio, Inc.seekingalpha.com - December 22 at 10:10 AMMustang Bio: Departure Of Directors Or Certain Officers; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officerscbonds.com - December 14 at 5:42 PMMustang Bio files to sell 2.74M shares of common stock for holdersmsn.com - December 12 at 1:26 PMMustang Bio’s Positive Financial Performance and Promising Clinical Developments Drive Buy Ratingmarkets.businessinsider.com - November 15 at 8:45 PMMustang Bio, Inc.: Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlightsfinanznachrichten.de - November 15 at 3:44 PMMustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - November 2 at 10:51 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptinyxNASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Correvio PharmaNASDAQ:CORVCorrevio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.Eton PharmaceuticalsNASDAQ:ETONEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.